Literature DB >> 29531902

Putting the brakes on CTLA-4 inhibition in lung cancer?

Meghan J Mooradian1, Justin F Gainor1.   

Abstract

Entities:  

Year:  2018        PMID： 29531902      PMCID： PMC5835619          DOI： 10.21037/tlcr.2018.01.05

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  23 in total

1.  Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.

Authors:  Amita Patnaik; S Peter Kang; Drew Rasco; Kyriakos P Papadopoulos; Jeroen Elassaiss-Schaap; Muralidhar Beeram; Ronald Drengler; Cong Chen; Lon Smith; Guillermo Espino; Kevin Gergich; Liliana Delgado; Adil Daud; Jill A Lindia; Xiaoyun Nicole Li; Robert H Pierce; Jennifer H Yearley; Dianna Wu; Omar Laterza; Manfred Lehnert; Robert Iannone; Anthony W Tolcher
Journal:  Clin Cancer Res       Date:  2015-05-14       Impact factor: 12.531

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 3.  The interplay of immunotherapy and chemotherapy: harnessing potential synergies.

Authors:  Leisha A Emens; Gary Middleton
Journal:  Cancer Immunol Res       Date:  2015-05       Impact factor: 11.151

4.  Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Authors:  Scott Antonia; Sarah B Goldberg; Ani Balmanoukian; Jamie E Chaft; Rachel E Sanborn; Ashok Gupta; Rajesh Narwal; Keith Steele; Yu Gu; Joyson J Karakunnel; Naiyer A Rizvi
Journal:  Lancet Oncol       Date:  2016-02-06       Impact factor: 41.316

5.  Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.

Authors:  Rituparna Das; Rakesh Verma; Mario Sznol; Chandra Sekhar Boddupalli; Scott N Gettinger; Harriet Kluger; Margaret Callahan; Jedd D Wolchok; Ruth Halaban; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  J Immunol       Date:  2014-12-24       Impact factor: 5.422

6.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

7.  Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Authors:  Martin Reck; Alexander Luft; Aleksandra Szczesna; Libor Havel; Sang-We Kim; Wallace Akerley; Maria Catherine Pietanza; Yi-Long Wu; Christoph Zielinski; Michael Thomas; Enriqueta Felip; Kathryn Gold; Leora Horn; Joachim Aerts; Kazuhiko Nakagawa; Paul Lorigan; Anne Pieters; Teresa Kong Sanchez; Justin Fairchild; David Spigel
Journal:  J Clin Oncol       Date:  2016-11-01       Impact factor: 44.544

Review 8.  Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.

Authors:  Stanleyson V Hato; Andrea Khong; I Jolanda M de Vries; W Joost Lesterhuis
Journal:  Clin Cancer Res       Date:  2014-06-01       Impact factor: 12.531

9.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

Authors:  M Reck; I Bondarenko; A Luft; P Serwatowski; F Barlesi; R Chacko; M Sebastian; H Lu; J-M Cuillerot; T J Lynch
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

Review 10.  CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.

Authors:  Elizabeth I Buchbinder; Anupam Desai
Journal:  Am J Clin Oncol       Date:  2016-02       Impact factor: 2.339
View more
  3 in total

Review 1.  Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

Authors:  Thaiz Rivera Vargas; Lionel Apetoh
Journal:  Front Immunol       Date:  2019-05-29       Impact factor: 7.561

Review 2.  SARS-COV-2 infection and lung tumor microenvironment.

Authors:  Naila Malkani; Muhammad Usman Rashid
Journal:  Mol Biol Rep       Date:  2021-01-23       Impact factor: 2.316

3.  The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases.

Authors:  Fabio Cofano; Matteo Monticelli; Marco Ajello; Francesco Zenga; Nicola Marengo; Giuseppe Di Perna; Roberto Altieri; Paola Cassoni; Luca Bertero; Antonio Melcarne; Fulvio Tartara; Alessandro Ducati; Diego Garbossa
Journal:  Cancer Control       Date:  2019 Jan-Dec       Impact factor: 3.302
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.